Summary:

- The article discusses a new drug candidate called EPPS that has shown promise in reversing memory loss and cognitive decline associated with Alzheimer's disease in animal studies.
- The drug works by targeting a specific protein called tau, which is a hallmark of Alzheimer's disease. It is believed to help restore normal tau function and improve cognitive function in Alzheimer's patients.
- The drug has successfully completed Phase 1 clinical trials and is now moving on to larger-scale Phase 2 trials to further evaluate its safety and efficacy in human patients with Alzheimer's disease.